Bridging the gap between scientific discovery and investment-ready innovation for rare disease breakthroughs.
ERDERA Technology Accelerator
The ERDERA Technology Accelerator advances the enabling technologies that make rare-disease therapies possible. We bring public and private partners together to mature, validate, and streamline advanced therapy platforms so promising discoveries can move faster, safer, and more efficiently toward the clinic.
By strengthening shared technological toolboxes for the rare disease community, we help reduce development risk and accelerate translation across multiple indications.
You are a technology developer…
…working on enabling technologies for rare-disease therapies within academia, a research infrastructure, an SME, or industry.
…developing platforms such as viral or non-viral delivery systems, gene-editing tools, therapeutic RNAs, or analytical and manufacturing solutions.
…looking to improve robustness, scalability, comparability, or clinical relevance of your technology through collaboration and real-world feedback.
If this sounds like you, the Technology Accelerator can help.
The Technology Accelerator supports partners by:
Advancing enabling ATMP technologies, including:
Adeno-associated Virus (AAVs)
Messenger RNA (mRNA)
Lipid Nanoparticles, Extracellular Vesicles, Biohybrids
Gene Editing Tools
Addressing key technical bottlenecks across:
Delivery efficiency and tissue targeting
Manufacturing and scale-up
Analytical characterisation and quality control
Evaluation of therapy response, safety, and immunogenicity
Facilitating pre-competitive collaboration between public and private stakeholders to strengthen shared technology platforms.
Aligning technology development with translational and clinical needs in rare diseases.
Advancing enabling ATMP technologies, including:
- Adeno-associated Virus (AAVs)
- Messenger RNA (mRNA)
- Lipid Nanoparticles, Extracellular Vesicles, Biohybrids
- Gene Editing Tools
Addressing key technical bottlenecks across:
- Delivery efficiency and tissue targeting
- Manufacturing and scale-up
- Analytical characterisation and quality control
- Evaluation of therapy response, safety, and immunogenicity
Networking
Facilitating pre-competitive collaboration between public and private stakeholders to strengthen shared technology platforms.
Alignment
Aligning technology development with translational and clinical needs in rare diseases.
Robust, well-validated enabling technologies are essential for translating rare-disease discoveries into viable therapies. By strengthening these foundations, the Technology Accelerator supports not just individual projects but the entire rare-disease innovation ecosystem.
Understand the concept of ATMPs with this Knowledge Pill
The role of National Mirror Groups (NMGs)
Latest relevant publications
